Published in final edited form as:

Bioorg Med Chem Lett. 2010 February 15; 20(4): 1420–1423. doi:10.1016/j.bmcl.2009.12.089.

Novel *bis*-2,2,6,6-tetramethylpiperidine (*bis*-TMP) and *bis*-mecamylamine antagonists at neuronal nicotinic receptors mediating nicotine-evoked dopamine release

Zhenfa Zhang, Marharyta Pivavarchyk, K. Leela Subramanian, A. Gabriela Deaciuc, Linda P. Dwoskin, and Peter A. Crooks*

College of Pharmacy, Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536-0082

Abstract

By linking two or three mecamylamine or 2,2,6,6-tetramethylpiperidine (TMP) molecules together via a linear lipophilic *bis*-methylene linker or a specially designed conformationally restricted *tris*-linker, a series of *bis*- and *tris*-tertiary amine analogs has been synthesized and evaluated as potent antagonists at nAChRs mediating nicotine-evoked [³H]dopamine release from rat striatal slices. Compounds **7e**, **14b** and **16** demonstrated high potency in decreasing nicotine-evoked [³H]dopamine release (IC₅₀=2.2, 46, and 107 nM, respectively). The preliminary structure-activity data obtained with these new analogs suggest the importance of the length of the methylene linker in the *bis*-analog series. Such *bis*-tertiary amino analogs may provide a new strategy for the design of drugable ligands that have high inhibitory potency against nAChRs mediating nicotine-evoked dopamine release in striatum, which have been suggested to be target receptors of interest in the development of potential smoking cessation therapies.

Keywords

nicotinic acetylcholine receptor; quaternary ammonium; dopamine release; nicotine addiction

Tobacco smoking is the number one health problem accounting for more illnesses and deaths in the US than any other single factor.¹ Despite some success of currently available pharmacotherapies, relapse rates continue to be high, indicating that novel medications are still needed.² Based on the observation that the nonselective nicotinic acetylcholine receptor (nAChR) antagonist, mecamylamine (1, Fig. 1) has some efficacy as a tobacco use cessation agent, but is limited by its peripherally-mediated side-effects, which range from constipation to hypotension,³ we hypothesized that subtype-selective nAChR antagonists will have both efficacy and therapeutic advantages (i.e., limited sideeffect profile) as tobacco use cessation agents. We concluded that antagonist molecules that selectively inhibit central nAChRs mediating nicotine (NIC)-evoked dopamine (DA) release will decrease NIC self-administration and/or cue-induced reinstatement of NIC seeking, and thus have potential as effective and safe pharmacotherapeutics for the treatment of NIC addiction.⁴

© 2009 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: +1 859 257 1718; fax: +1 859 257 7585; pcrooks@email.uky.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The classical discovery that the *bis*-trialkylammonium nAChR channel blockers, hexamethonium and decamethonium, exhibit subtype selectivity between ganglionic nAChRs and muscle type nAChRs,⁵ led us to adopt a similar molecular approach in the discovery of antagonists of nAChRs mediating NIC-evoked DA release. This resulted in the identification of a series of novel structural scaffolds incorporating both flexible and conformationally restrained *bis*-,^{6,7} *tris*-⁸ and *tetrakis*-⁹ frameworks to which were appended a variety of quaternary ammonium head-groups. Initially, our lead candidate, *N,N*-dodecyl-1,12-diyl-*bis*-3-picolinium dibromide (bPiDDB, **2**, Fig. 1),¹⁰ a brain bioavailable azaaromatic quaternary ammonium analog,¹¹ was demonstrated to be more selective than mecamlamine for nicotinic receptors inhibiting NIC-evoked DA release, and was the first example of a small molecule version of the $\alpha 6$ -selective neuropeptide, α -conotoxin MII.¹² Structural iterations on bPiDDB included the development of novel scaffolds to which three or four cationic head groups were appended (i.e. *tris*- and *tetrakis*-azaaromatic quaternary ammonium sublibraries), which afforded a selection of unique, high potency analogs that inhibited NIC-evoked DA release.^{8,9} Results from pharmacokinetic studies utilizing radiolabeled ¹⁴C-bPiDDB indicated that despite their cationic charge and polarity, the azaaromatic *bis*- quaternary ammonium analogs were brain bioavailable after subcutaneous delivery, due to their facilitated transport via the blood brain barrier choline transporter,^{11,13} although bPiDDB has limited bioavailability when given by the oral route (Albayati et al., unpublished data). Since oral delivery is the preferred clinical route for development of a pharmaceutical product, we sought to optimize our synthetic strategies to focus on the design of analogs with improved oral bioavailability while maintaining inhibitory potency at $\alpha 6$ -containing nAChRs.

The current study was initiated to determine if quaternary ammonium head groups in the structures of the first generation *bis*- and *tris*-analogs could be replaced with a variety of azacyclic tertiary amino moieties that have pKa values in the range 7-9. This would allow the molecules to be protonated under physiological conditions (i.e., they will be cationic), with the ability to partition through cell membranes. In the selection of the tertiary amino head group, we chose to utilize small molecule tertiary amines that were previously shown to be noncompetitive antagonists at nAChRs,^{14,15} since our *bis*- and *tris*- quaternary amino analogs do not appear to interact with the acetylcholine binding site.

Mecamlamine (**1**, Fig. 1) is an example of such an azacyclic amino compound that is a non-selective nAChR channel blocker and non-competitive inhibitor of NIC-evoked DA release. Other examples of azacyclic compounds that are nAChR channel blockers, include the azacyclic tertiary amine, 1,2,2,6,6-pentamethylpiperidine (pempidine) and its *N*-demethylated analog, TMP (**3**, Fig. 1).¹⁴ In this regard, it has already been reported that *bis*-(2,2,6,6-tetramethyl-4-piperidiny)l sebacate (BTMPS; **4**, Fig. 1) is a non-competitive, use-dependent antagonist at nAChRs.¹⁵ Thus, TMP and mecamlamine were incorporated as the tertiary amine replacement head groups in the current study because, like the azaaromatic *bis*-quaternary ammonium analogs, they would be predicted to not interact with the acetylcholine binding site on nAChRs.

TMP analogs were synthesized by linking two TMP molecules through the same lipophilic 1,12-dodecanyl linker as in bPiDDB. The linker length was also varied from 8-12 methylene units, in order to determine the effect of linker length on potency for inhibition of NIC-evoked [³H]DA release. *N*-alkylation of TMP with the appropriate diiodoalkane (**6**, Scheme 1) was employed for the linking chemistry. Initial attempts at linking two molecules of TMP with 1,12-dibromododecane in the presence of potassium carbonate in refluxing acetonitrile produced a mixture containing the desired product accompanied by many other components, including the mono-alkylation product, elimination products of 1,12-dibromododecane, i.e. bromododecenes, and monoalkylated elimination products. Steric hindrance caused by the

four α -methyl groups of TMP also impeded efficient *N*-alkylation. Thus, the more reactive 1,12-diiodododecane was employed in the presence of an excess of TMP, and the reaction was carried out in a sealed tube. These conditions afforded the desired product, **7e**, in good yield (60-70%). Compounds **7a-7d** were prepared in a similar fashion from the appropriate diiodoalkane.

Since there is a chiral center in the mecamlamine molecule, the incorporation of two or more ($\pm$)-mecamlamine moieties into one *bis* or *tris*-molecule becomes complicated, due to the generation of multiple diastereomeric products. It has been shown that there is little difference in the IC₅₀ values of *S*(+)- and *R*(-)-mecamlamine at a given nAChR receptor subtype.¹⁵ However, in oocyte expression systems, there appears to be significant differences in the off-rates of the two mecamlamine enantiomers from nAChR receptors. Specifically, *S*(+)-mecamlamine appears to dissociate more slowly from $\alpha 4\beta 2$ and $\alpha 3\beta 4$ receptors than does *R*(-)-mecamlamine.¹⁶ The more active *S*(+)-mecamlamine enantiomer was employed in the synthesis of the *bis*- and *tris*-mecamlamine analogs, in order to simplify the synthetic process and to better understand the SAR. The preparation of *S*(+)-mecamlamine and the *bis*- and *tris*-mecamlamine analogs **14a**, **14b**, and **16** are summarized in Scheme 2. Commercially available (-)-camphene (**6**, Scheme 2, 80% chemical purity) was treated with sulfuric acid and potassium thiocyanate to afford isothiocyanate **9** and a small amount of the corresponding thiocyanate. Reduction of this intermediate with LAH afforded crude *S*(+)-mecamlamine that was contaminated with the corresponding thioalcohol generated from the thiocyanate. After acid extraction to remove the thioalcohol, the resulting *S*(+)-mecamlamine was resolved further with camphorsulfonic acid to afford the chirally pure *S*(+)-enantiomer, which was then utilized in the *N*-alkylation reaction with the appropriate di- or tri-iodo intermediate.

The same procedure as utilized in the synthesis of analogs **7a-7e** could be adopted to afford the *bis*-mecamlamine analogs. However, with *S*(+)-mecamlamine, the employment of a large excess of starting mecamlamine is not practical, due to the amount of effort involved in the preparation of this compound. Thus, another procedure was devised, and the *S*(+)-mecamlamine was initially *N*-acylated with either 1,10-decandioic chloride or 1,12-dodecandioic chloride to afford the *bis*-amides **13a** and **13b**, respectively, which were each cleanly reduced by LAH to afford **14a** and **14b**, respectively. Since compound **5** (tPy3PiB, Fig. 1) was considered to be a valuable lead compound in our systematic structural elaboration of the original quaternary ammonium series, a *tris*-analog of **5** was synthesized in which the 3-picolinium head-groups had been replaced with *S*(+)-mecamlamine moieties (i.e., analog **16**). The preparation of the starting tribromide **15a** is reported in our previous study.⁸ Tribromide **15a** was transformed into the corresponding tri-iodide **15b** and this intermediate was then utilized in the synthesis of **16**.

Utilizing an initial probe concentration of 100 nM, compounds **7a-7e**, **14a**, **14b**, and **16** were evaluated for their ability to inhibit NIC-evoked [³H]DA release from superfused rat striatal slices. The most active compounds (>50% inhibition in the probe assay) were then evaluated across a full concentration range, to determine IC₅₀ and I_{max} values for inhibition of NIC-evoked [³H]DA release (Table 1).

[³H]DA release assays were performed according to a previously published method.¹⁷ Initially, analog-induced inhibition of nicotine-evoked [³H]DA release was determined using 10 μ M NIC and 100 nM analog concentrations. Amount of inhibition is presented as a percentage of the response to NIC under control conditions (in the absence of analog) and the results are provided in Table 1 and Fig. 2. Full concentration response (1 nM to 10 μ M) was performed for the most promising analogs (Table 1 and Fig. 3), and IC₅₀ and I_{max}

values were determined using an iterative nonlinear least squares curve-fitting program, PRISM version 4.0 (GraphPAD Software, Inc., San Diego, CA).

The current study introduces for the first time a novel series of nAChR antagonists produced by incorporating TMP or mecamlamine molecules into a *bis*- or *tris*- structural scaffold. In our search for novel nAChR antagonists with potential as smoking cessation agents, the NIC-evoked [³H]DA release assay was used as an initial screen to identify lead compounds, since the ability of NIC to release DA is believed to be associated with the rewarding properties of NIC. Also, the neuronal tissue utilized in this assay, striatum, is important for identifying and anticipating reward and organizing goal-directed behavior.¹⁸ Compounds **7e**, **14b** and **16** were identified as hits in the single 100 nM concentration screen because they produced greater than 50% inhibition of NIC-evoked [³H]DA release (Fig. 2, Table 1). From previous studies, we have found that the length of the linker unit plays an important role in the effect of these *bis*- and *tris*-compounds in inhibiting NIC-evoked striatal [³H]DA release. The linker length SAR was evaluated over a C₈ to C₁₂ methylene linker range with TMP as the head group moiety (analogs **7a-7e**). From the results obtained in the single concentration screen, with the exception of C₈, all analogs inhibited NIC-evoked [³H]DA release, with **7e**, the C₁₂-linker derivative, being the most efficacious compound in the series. The other TMP derivatives were less efficacious, and there was a noticeable dependence of inhibitory potency on linker length. Except for the C₈-linker derivative **7a**, the other four TMP analogs exhibited systematically higher inhibition, as linker length was increased. In the full concentration–response analysis, **7e** was observed to inhibit NIC-evoked [³H]DA release from superfused rat striatal slices with an IC₅₀ value of 2.2 nM and an I_{max} of 87%. This compares very favorably with bPiDDB (IC₅₀=2 nM; I_{max}=78%). Thus, replacing the two 3-picolinium head groups of bPiDDB with TMP moieties resulted in a *bis*-tertiary amino analog with similar inhibitory potency. Analog **7e** can therefore be considered as a lead compound, and a more “drugable” analog of bPiDDB.

With these encouraging results, we next investigated the *bis*-analogs containing *S*-(+)-mecamlamine as the replacement head-group for the 3-picolinium moiety in bPiDDB. Analogs with C₁₀- and C₁₂-methylene linkers were evaluated. Similar to **7e**, the C₁₂ mecamlamine derivative, **14b** (bMecDD), was designated as a hit (52% inhibition) in the NIC-evoked [³H]DA release probe assay (Fig. 2, Table 1). Analog **14b** afforded an IC₅₀ of 46 nM with an I_{max} of 83% in the full concentration response assay. The greatest percentile inhibition in the probe assay was obtained with the *tris*-mecamlamine analog **16** (tMecBPY; 73% inhibition, Fig. 2). Compound **16** was 100-fold more potent than mecamlamine in inhibiting NIC-evoked DA release, with a IC₅₀ value of 107 nM and an I_{max} of 62% (Fig. 3, Table 1). These results clearly demonstrate that both quaternary ammonium and tertiary amino head-groups can be utilized in the design of *bis*- and *tris*-analogs as potent inhibitors of nAChRs which mediate NIC-evoked DA release.

It should be noted that unlike the prototypical CNS-active nAChR inhibitor mecamlamine, **14b** and **16** did not inhibit NIC-evoked DA release from striatal slices completely (I_{max}=83% and 62%, respectively). These results are in agreement with previous literature indicating that multiple nAChRs mediate NIC-evoked DA release, and that **14b** and **16** are likely acting as antagonists at only a subset of these nAChR subtypes. This observation is consistent with previous results showing that TMPH blocked some, but not all, of the CNS effects of NIC, indicating that this compound has a unique selectivity for specific nAChR receptor subtypes in the brain.¹⁵

In conclusion, linking TMP and mecamlamine head groups with lipophilic n-alkane linkers of variable lengths, or with a conformationally restrained *tris*-linker moiety, affords a novel series of compounds with tertiary amine head groups replacing the quaternary ammonium

head groups present in the nAChR antagonists, bPiDDB and tPy3PiB. These molecules demonstrated high potency in inhibiting NIC-evoked DA release from striatal tissue, and can be considered lead compounds in the development of therapeutic agents to treat nicotine addiction. Since such tertiary amino derivatives will have improved membrane permeation capabilities due to their physicochemical properties, and have the potential to be orally effective with good brain bioavailability.

Acknowledgments

This work was supported by NIH/NIDA Grant U19 DA017548.

References and Notes

1. <http://www.who.int/tobacco/en/>
2. George TP, O'Malley SS. Trends Pharmacol Sci. 2004; 25:42. [PubMed: 14723978]
3. Rose JE, Westman EC, Behm FM, Johnson MP, Goldberg JS. Pharmacol Biochem Behav. 1999; 62:165. [PubMed: 9972860]
4. Dwoskin LP, Pivavarchyk M, Joyce BM, Neugebauer NM, Zheng G, Zhang Z, Bardo MT, Crooks PA. Nebr Symp Motiv. 2009; 55:31. [PubMed: 19013938]
5. Rang HP. Postgrad Med J. 1981; 57(Suppl 1):89. [PubMed: 6117850]
6. Zheng G, Zhang Z, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Bioorg Med Chem Lett. 2007; 17:6734. [PubMed: 18029180]
7. Zhang Z, Lockman PR, Mittapalli RK, Allen DD, Dwoskin LP, Crooks PA. Bioorg Med Chem Lett. 2008; 18:5622. [PubMed: 18793853]
8. Zheng G, Sumithran SP, Deaciuc AG, Dwoskin LP, Crooks PA. Bioorg Med Chem Lett. 2007; 17:6701–6. [PubMed: 17977723]
9. Zheng G, Zhang Z, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Bioorg Med Chem Lett. 2008; 18:5753. [PubMed: 18851914]
10. Dwoskin LP, Sumithran SP, Zhu J, Deaciuc AG, Ayers JT, Crooks PA. Bioorg Med Chem Lett. 2004; 14:1863. [PubMed: 15050617]
11. Albayati ZA, Dwoskin LP, Crooks PA. Drug Metab Dispos. 2008; 36:2024. [PubMed: 18617603]
12. Dwoskin LP, Wooters TE, Sumithran SP, Siripurapu KB, Joyce BM, Lockman PR, Manda VK, Ayers JT, Zhang Z, Deaciuc AG, McIntosh JM, Crooks PA, Bardo MT. J Pharmacol Exp Ther. 2008; 326:563. [PubMed: 18460644]
13. Lockman PR, Manda VK, Geldenhuys WJ, Mittapalli RK, Thomas F, Albayati ZF, Crooks PA, Dwoskin LP, Allen DD. J Pharmacol Exp Ther. 2008; 324:244. [PubMed: 17921191]
14. Damaj MI, Wiley JL, Martin BR, Papke RL. Eur. J. Pharmacol. 2005; 521:43. Papke RL, Buhr JD, Francis MM, Choi KI, Thinschmidt JS, Horenstein NA. Mol Pharmacol. 2005; 67:1977. [PubMed: 15761116]
15. Graham JH, Papke RL, Buccafusco JJ. Curr Alzheimer Res. 2005; 2:141–7. [PubMed: 15974911] Papke RL, Craig AG, Heinemann SF. J Pharmacol Exp Ther. 1994; 268:718. [PubMed: 8113983]
16. Papke RL, Sanberg PR, Shytle RD. J Pharmacol Exp Ther. 2001; 297:646–56. [PubMed: 11303054]
17. Wilkins LH, Grinevich VP, Ayers JT, Crooks PA, Dwoskin LP. J. Pharmacol. Exp. Ther. 2003; 304:400. [PubMed: 12490617]
18. Laviolette SR, van der Kooy D. Nat Rev Neurosci. 2004; 5:55–65. [PubMed: 14708004] Schultz W. Neuron. 2002; 36:241. [PubMed: 12383780] Samejima K, Ueda Y, Doya K, Kimura M. Science. 2005; 310:1337. [PubMed: 16311337]

Figure 1. Structures of mecamylamine (**1**), bPiDDB (**2**), TMP (**3**), BTMPS (**4**), and tPy3PiB (**5**).

Figure 2.

S-(-)-Nicotine-evoked fractional [^3H]DA release from rat striatal slices superfused with 100 nM **14a** (bMecD), **14b** (bMecDD) and **16** (tMecBPY). Data are expressed as mean $\pm$ SEM fractional release as a percent of basal fractional release, i.e., percent of samples prior to the addition of analog or nicotine. Control represents the amount of fractional release evoked by S-(-)-nicotine in the absence of analog; n = 3 rats/analog.

Figure 3.

Analog **16** (tMecBPY) inhibited S-(–)-nicotine-evoked $[^3\text{H}]\text{DA}$ overflow from rat striatal slices in a concentration-dependent manner. Control represents $[^3\text{H}]\text{DA}$ overflow in response to 10 μM nicotine in the absence of analog and is expressed as a percent of tissue $[^3\text{H}]$ content, mean $\pm$ S.E.M, $n = 4$ rats.

Scheme 1.

Synthesis of *bis*-TMP analogs **7a-7e**, and *bis*-*S*-(+)-mecamylamine analogs **14a** and **14b**.

Scheme 2.
Synthesis of *tris*-mecamylamine analog **16**

Table 1Inhibition of nicotine-evoked [³H]DA release from superfused rat striatal slices.^a

Compound			DA Release	
No.	Head group	Linker	% Inhibition (100 nM) ^a	IC ₅₀ nM (CI) and I _{max} ^b
7a		1,8-Octane	18±?%	ND ^c
7b		1,9-Nonanol	5±5%	ND
7c		1,10-Decane	22±8%	ND
7d		1,11-Undecane	36±10%	ND
7e		1,12-Dodecane	56±14%	2.2 (0.9-5.2) I _{max} =87%
14a		1,10-Decane	35±16%	319(143-712) I _{max} =90%
14b		1,12-Dodecane	52±7%	46 (8-259) I _{max} =83%
16		Tris-linker	73±2%	107 (25-443) I _{max} =62%
2		1,12-Dodecane (bPiDDB)	ND	2.0±0.1 I _{max} =78%
5		Tris-linker (tPy3PiB)	40 ±12 %	0.2±0.07 I _{max} =67%

^aPercentage of inhibition at 100 nM are presented unless otherwise specified. Each value represents data from at least 3 independent experiments, each performed in duplicate.

^bIC₅₀ and I_{max} from full concentration response assays; data from 4-6 independent experiments.

^cNot determined